Tag: Biologics
GenSight Biologics wants to extend its visibility beyond April 2024 – 04/05/2024 at 10:31
(AOF) – GenSight Biologics (-5.89% to 0.39 euros) announces that its cash position stands at 2.2 million euros as of March 31, 2024, compared to 2.1 million euros as of…
GenSight Biologics wants to extend its visibility beyond April 2024
(AOF) – GenSight Biologics (-5.89% to 0.39 euros) announces that its cash position stands at 2.2 million euros as of March 31, 2024, compared to 2.1 million euros as of…
Gensight Biologics reduces its losses in 2023 – 03/22/2024 at 6:25 p.m.
(AOF) – Gensight Biologics posts an operating loss of 29.7 million euros in 2023 compared to 27.8 million euros in 2022. This increase of 1.9 million euros is mainly linked…
Gensight Biologics cuts losses in 2023
(AOF) – Gensight Biologics posts an operating loss of 29.7 million euros in 2023 compared to 27.8 million euros in 2022. This increase of 1.9 million euros is mainly linked…
What are biologics?
Biologics (also biologics or biologics) are genetically engineered drugs that are similar to the body’s own substances and specifically influence various regulatory mechanisms of the body. Read here how and…
GenSight Biologics: new data on Lumevoq presented this week
(AOF) – GenSight Biologics today announced that new data and scientific analyzes relating to the Lumevoq gene therapy will be presented at the 50th Annual Meeting of the North American…
Treating psoriasis: What to do if you have psoriasis?
There are various options available to treat psoriasis – from ointments to systemic medications and light therapy. Find out here how you can effectively treat psoriasis and which methods are…
Gensight Biologics SA: The Goldman Sachs Group, Inc. crosses the threshold of 5% of capital
LR source AMF Published on 02/16/2024 at 10:00 a.m. Photo credit © Euronext (Boursier.com) — The company The Goldman…
GenSight Biologics: shareholders hand over 5 ME
By Arnaud Bivès Published on 02/08/2024 at 08:53 a.m. (Boursier.com) — GenSight whose cash flow situation was particularly tense, has just completed…
GenSight Biologics: Laurence Rodriguez succeeds Bernard Gilly
By Alexandra Saintpierre Published on 01/16/2024 at 7:38 p.m. Photo credit © NissierPictures (Boursier.com) — The Board of…
Gensight Biologics: visibility until mid-February 2024 – 12/27/2023 at 09:43
(AOF) – Gensight Biologics announces that its cash flow horizon has been extended from mid-January to mid-February 2024. The biotech specializing in innovative gene therapies for retinal neurodegenerative diseases and…
GenSight Biologics: Laurence Rodriguez (ex-Sanofi) appointed CEO
(AOF) – GenSight Biologics announced the appointment of Laurence Rodriguez as Chief Executive Officer. The biotech specialist in gene therapies for retinal neurodegenerative diseases and central nervous system disorders specifies…